BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42:125-147. [PMID: 21846426 DOI: 10.1017/s003329171100105x] [Cited by in Crossref: 230] [Cited by in F6Publishing: 243] [Article Influence: 19.2] [Reference Citation Analysis]
Number Citing Articles
1 Ranpara M, Orava M. Baseline monitoring of atypical antipsychotics at a Family Medicine Teaching Unit (FMTU) in Ontario, Canada. Personalized Medicine in Psychiatry 2023;37-38:100099. [DOI: 10.1016/j.pmip.2022.100099] [Reference Citation Analysis]
2 Johnson CF, Earle-payne K. Identifying mental health training needs of general practice pharmacy workforce to advance practice: a training needs analysis survey. Int J Clin Pharm 2022. [DOI: 10.1007/s11096-022-01486-5] [Reference Citation Analysis]
3 Gonzales G, Tornes K, Saklad SR. Stewardship applied to antipsychotics: Development of an antipsychotic stewardship program in inpatient settings for monitoring and optimizing outcomes. Mental Health Clinician 2022;12:320-326. [DOI: 10.9740/mhc.2022.10.320] [Reference Citation Analysis]
4 Ai Y, Zhao J, Liu H, Li J, Zhu T. The relationship between diabetes mellitus and attention deficit hyperactivity disorder: A systematic review and meta-analysis. Front Pediatr 2022;10:936813. [DOI: 10.3389/fped.2022.936813] [Reference Citation Analysis]
5 Hunt A, St John-smith P, Abed R. The Biopsychosocial Model Advanced by Evolutionary Theory. Evolutionary Psychiatry 2022. [DOI: 10.1017/9781911623625.004] [Reference Citation Analysis]
6 Cloete SA, Daniels F. Perceptions of Mental Health Nurses Regarding Metabolic Syndrome at a Public Tertiary Psychiatric Hospital in Western Cape, South Africa. AJNM 2022;24. [DOI: 10.25159/2520-5293/9469] [Reference Citation Analysis]
7 Chan JKN, Chu RST, Hung C, Law JWY, Wong CSM, Chang WC. Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients With Severe Mental Illness: A Systematic Review and Meta-analysis. Schizophr Bull 2022:sbac070. [PMID: 35786737 DOI: 10.1093/schbul/sbac070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Fontaine J, Chin E, Provencher JF, Rainone A, Wazzan D, Roy C, Rej S, Lordkipanidze M, Dagenais-Beaulé V. Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study - a cross-sectional study. BMJ Open 2022;12:e055454. [PMID: 35414553 DOI: 10.1136/bmjopen-2021-055454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Trigueiro AJP, Ramirez J, Hennessey E, Beqiri M. Metabolic Syndrome Identification in Patients Treated With Second-Generation Antipsychotic Medications. J Psychosoc Nurs Ment Health Serv 2022;:1-8. [PMID: 35316124 DOI: 10.3928/02793695-20220314-01] [Reference Citation Analysis]
10 Kølbæk P, Thorgaard MV, Grooss AS, Selvanathan T, Larsen SF, Speed M, Dines D, Østergaard SD. Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ). J Psychopharmacol 2022;:2698811221077196. [PMID: 35234056 DOI: 10.1177/02698811221077196] [Reference Citation Analysis]
11 Sudarshan Y, Cheung BMY. Hypertension and psychosis. Postgrad Med J 2022:postgradmedj-2021-141386. [PMID: 35074801 DOI: 10.1136/postgradmedj-2021-141386] [Reference Citation Analysis]
12 Schimmenti S, Maselli FMC, Tosato S. Targeting Metabolic Abnormalities in Mental Health Prevention Strategies. Prevention in Mental Health 2022. [DOI: 10.1007/978-3-030-97906-5_13] [Reference Citation Analysis]
13 Gardner KN. Part I: Interactive case: Adverse effects associated with antipsychotic therapy. J Am Coll Clin Pharm 2021;4:1618-23. [DOI: 10.1002/jac5.1563] [Reference Citation Analysis]
14 Schizophrenia and Related Psychoses. The Maudsley Prescribing Guidelines in Psychiatry 2021. [DOI: 10.1002/9781119870203.mpg001] [Reference Citation Analysis]
15 Schuster MP, Borkent J, Chrispijn M, Ioannou M, Doornbos B, Burger H, Haarman BCM. Increased prevalence of metabolic syndrome in patients with bipolar disorder compared to a selected control group-a Northern Netherlands LifeLines population cohort study. J Affect Disord 2021;295:1161-8. [PMID: 34706429 DOI: 10.1016/j.jad.2021.08.139] [Reference Citation Analysis]
16 Dias ICS, de Campos-Carli SM, Vieira ELM, Mota APL, Azevedo PS, Anício VTDS, Guimarães FC, Mantovani LM, Cruz BF, Teixeira AL, Salgado JV. Adiponectin and Stnfr2 peripheral levels are associated with cardiovascular risk in patients with schizophrenia. J Psychiatr Res 2021:S0022-3956(21)00669-5. [PMID: 34785039 DOI: 10.1016/j.jpsychires.2021.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Berge J, Abri P, Andell P, Movahed P, Ragazan DC. Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality. J Psychiatr Res 2021:S0022-3956(21)00672-5. [PMID: 34785037 DOI: 10.1016/j.jpsychires.2021.11.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Teasdale SB, Moerkl S, Moetteli S, Mueller-Stierlin A. The Development of a Nutrition Screening Tool for Mental Health Settings Prone to Obesity and Cardiometabolic Complications: Study Protocol for the NutriMental Screener. Int J Environ Res Public Health 2021;18:11269. [PMID: 34769787 DOI: 10.3390/ijerph182111269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chieh AY, Bryant BM, Kim JW, Li L. Systematic review investigating the relationship between autism spectrum disorder and metabolic dysfunction. Res Autism Spectr Disord 2021;86:101821. [PMID: 36570741 DOI: 10.1016/j.rasd.2021.101821] [Reference Citation Analysis]
20 Azfr Ali RS, Jalal Z, Paudyal V. Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? Gen Psychiatr 2021;34:e100561. [PMID: 34396043 DOI: 10.1136/gpsych-2021-100561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li W, Liu F, Liu R, Zhou X, Li G, Xiao S. APOE E4 is associated with hyperlipidemia and obesity in elderly schizophrenic patients. Sci Rep 2021;11:14818. [PMID: 34285334 DOI: 10.1038/s41598-021-94381-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chang WC, Chan JKN, Wong CSM, Hai JSH, Or PCF, Chen EYH. Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients With Psychotic Disorders: A Population-Based Cohort Study. Schizophr Bull 2020;46:774-84. [PMID: 32083305 DOI: 10.1093/schbul/sbaa013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
23 Medication Safety in Special Contexts. Medication Safety during Anesthesia and the Perioperative Period 2021. [DOI: 10.1017/9781108151702.010] [Reference Citation Analysis]
24 Stockbridge EL, Webb NJ, Dhakal E, Garg M, Loethen AD, Miller TL, Nandy K. Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data. BMC Health Serv Res 2021;21:69. [PMID: 33461561 DOI: 10.1186/s12913-020-06045-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Murru A, Anmella G, Giménez A, Vieta E. Bipolar disorders, obesity, and metabolic disturbances: Mechanisms and implications. Neurobiology of Bipolar Disorder 2021. [DOI: 10.1016/b978-0-12-819182-8.00022-3] [Reference Citation Analysis]
26 Romain AJ, Bernard P, Piché F, Kern L, Ouellet-plamondon C, Abdel-baki A, Roy M. Mens sana in corpore sano : l’intérêt de l’activité physique auprès des jeunes ayant eu un premier épisode psychotique. Santé mentale au Québec 2021;46:249. [DOI: 10.7202/1088185ar] [Reference Citation Analysis]
27 Fochtmann LJ, Medicus J, Hong SH. Performance in Practice: Practice Assessment Tool for the Care of Patients With Schizophrenia. Focus (Am Psychiatr Publ) 2020;18:402-23. [PMID: 33343252 DOI: 10.1176/appi.focus.20200034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Li R, Zhang Y, Zhu W, Ding C, Dai W, Su X, Dai W, Xiao J, Xing Z, Huang X. Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis. Sci Rep 2020;10:17028. [PMID: 33046806 DOI: 10.1038/s41598-020-73983-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
29 Berry A, Drake RJ, Yung AR. Examining healthcare professionals' beliefs and actions regarding the physical health of people with schizophrenia. BMC Health Serv Res 2020;20:771. [PMID: 32819374 DOI: 10.1186/s12913-020-05654-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Agaba DC, Migisha R, Katamba G, Ashaba S. Cardio-metabolic abnormalities among patients with severe mental illness at a Regional Referral Hospital in southwestern Uganda. PLoS One 2020;15:e0235956. [PMID: 32678850 DOI: 10.1371/journal.pone.0235956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Melamed OC, Hahn MK, Agarwal SM, Taylor VH, Mulsant BH, Selby P. Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies. Gen Hosp Psychiatry 2020;66:30-3. [PMID: 32645586 DOI: 10.1016/j.genhosppsych.2020.06.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
32 Češková E. Importance of side effects of antipsychotics and their monitoring in clinical practice - focused on paediatric and geriatric populations. Psychiatr pro Praxi 2020;21:16-18. [DOI: 10.36290/psy.2020.003] [Reference Citation Analysis]
33 Fehily CM, Bartlem KM, Wiggers JH, Wye PM, Clancy RV, Castle DJ, Wilson A, Rissel CE, Wutzke S, Hodder RK, Colyvas K, Murphy F, Bowman JA. Effectiveness of embedding a specialist preventive care clinician in a community mental health service in increasing preventive care provision: A randomised controlled trial. Aust N Z J Psychiatry 2020;54:620-32. [PMID: 32403938 DOI: 10.1177/0004867420914741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Taylor RW, Marwood L, Oprea E, DeAngel V, Mather S, Valentini B, Zahn R, Young AH, Cleare AJ. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. Int J Neuropsychopharmacol 2020;23:587-625. [PMID: 32402075 DOI: 10.1093/ijnp/pyaa033] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
35 Heiberg IH, Nesvåg R, Balteskard L, Bramness JG, Hultman CM, Naess Ø, Reichborn-Kjennerud T, Ystrom E, Jacobsen BK, Høye A. Diagnostic tests and treatment procedures performed prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand 2020;141:439-51. [PMID: 32022895 DOI: 10.1111/acps.13157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
36 Maj M. Beyond diagnosis in psychiatric practice. Ann Gen Psychiatry 2020;19:27. [PMID: 32322290 DOI: 10.1186/s12991-020-00279-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
37 Skonieczna-Żydecka K, Łoniewski I, Stachowska E, Marlicz W, Correll CU. Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics. Int J Neuropsychopharmacol 2020;23:491-5. [PMID: 32239144 DOI: 10.1093/ijnp/pyaa026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Tugwell BD, King DS, Kaiser SM. An Unexpected Case of Diabetic Ketoacidosis on the Psychiatry Ward: Olanzapine-Associated Adult Ketosis-Prone Type 2 Diabetes Mellitus. Canadian Journal of Diabetes 2020;44:216-218. [DOI: 10.1016/j.jcjd.2019.07.148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Rubio JM, Kane JM. How and when to use clozapine. Acta Psychiatr Scand 2020;141:178-89. [PMID: 31603988 DOI: 10.1111/acps.13111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
40 Aouira N, Khan S, Mcdermott B, Heussler H, Haywood A, Karaksha A, Bor W. Paper based vs. electronic records for clinical audit: Evidence of documentation of medication safety monitoring in youth prescribed antipsychotics. Children and Youth Services Review 2020;109:104666. [DOI: 10.1016/j.childyouth.2019.104666] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Correll CU, Sikich L, Reeves G, Johnson J, Keeton C, Spanos M, Kapoor S, Bussell K, Miller L, Chandrasekhar T, Sheridan EM, Pirmohamed S, Reinblatt SP, Alderman C, Scheer A, Borner I, Bethea TC, Edwards S, Hamer RM, Riddle MA. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry 2020;19:69-80. [PMID: 31922663 DOI: 10.1002/wps.20714] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 13.7] [Reference Citation Analysis]
42 Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020;19:61-8. [PMID: 31922669 DOI: 10.1002/wps.20699] [Cited by in Crossref: 134] [Cited by in F6Publishing: 144] [Article Influence: 44.7] [Reference Citation Analysis]
43 D. Rosenblat J, Mcintyre RS. Pharmacological Treatment of Major Depressive Disorder. Major Depressive Disorder 2020. [DOI: 10.1016/b978-0-323-58131-8.00008-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Carney R, Imran S, Law H, Folstad S, Parker S. Evaluation of the physical health of adolescent in-patients in generic and secure services: retrospective case-note review. BJPsych Bull 2020;44:95-102. [PMID: 31679539 DOI: 10.1192/bjb.2019.68] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Mitchell AJ, Vancampfort D, Manu P, Correll CU, Wampers M, van Winkel R, Yu W, De Hert M. Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study. PLoS One 2019;14:e0210674. [PMID: 31513598 DOI: 10.1371/journal.pone.0210674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Breslau J, Leckman-Westin E, Yu H, Han B, Pritam R, Guarasi D, Horvitz-Lennon M, Scharf DM, Pincus HA, Finnerty MT. Impact of a Mental Health Based Primary Care Program on Quality of Physical Health Care. Adm Policy Ment Health 2018;45:276-85. [PMID: 28884234 DOI: 10.1007/s10488-017-0822-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
47 Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Naess Ø, Ystrom E, Reichborn-Kjennerud T, Hultman CM, Nesvåg R, Høye A. Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand 2019;139:558-71. [PMID: 30844079 DOI: 10.1111/acps.13017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
48 Breslau J, Pritam R, Guarasi D, Horvitz-Lennon M, Finnerty M, Yu H, Leckman-Westin E. Predictors of Receipt of Physical Health Services in Mental Health Clinics. Community Ment Health J 2019;55:1279-87. [PMID: 30963350 DOI: 10.1007/s10597-019-00399-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Rødevand L, Steen NE, Elvsåshagen T, Quintana DS, Reponen EJ, Mørch RH, Lunding SH, Vedal TSJ, Dieset I, Melle I, Lagerberg TV, Andreassen OA. Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade. Acta Psychiatr Scand 2019;139:348-60. [PMID: 30697685 DOI: 10.1111/acps.13008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
50 Ward KM, Yeoman L, McHugh C, Kraal AZ, Flowers SA, Rothberg AE, Karnovsky A, Das AK, Ellingrod VL, Stringer KA. Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Pharmacotherapy 2018;38:638-50. [PMID: 29722909 DOI: 10.1002/phar.2119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
51 Stanislaus V, Bastiampillai T, Harris M, Battersby M. Care Plans in Community Mental Health: an Audit Focusing on People with Recent Hospital Admissions. J Behav Health Serv Res 2017;44:474-82. [PMID: 26940207 DOI: 10.1007/s11414-016-9504-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
52 Simoons M, Ruhé HG, van Roon EN, Schoevers RA, Bruggeman R, Cath DC, Muis D, Arends J, Doornbos B, Mulder H. Design and methods of the 'monitoring outcomes of psychiatric pharmacotherapy' (MOPHAR) monitoring program - a study protocol. BMC Health Serv Res 2019;19:125. [PMID: 30764821 DOI: 10.1186/s12913-019-3951-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
53 Vancampfort D, Firth J, Correll CU, Solmi M, Siskind D, De Hert M, Carney R, Koyanagi A, Carvalho AF, Gaughran F, Stubbs B. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 2019;18:53-66. [PMID: 30600626 DOI: 10.1002/wps.20614] [Cited by in Crossref: 97] [Cited by in F6Publishing: 104] [Article Influence: 24.3] [Reference Citation Analysis]
54 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. Therapie psychischer Erkrankungen 2019. [DOI: 10.1016/b978-3-437-24911-2.16001-8] [Reference Citation Analysis]
55 Al-sayed HM, Soliman WI. Potential Toxic Effects of Olanzapine on Metabolic Parameters in <i>de Novo</i> Paranoid Schizophrenic Patients. The Role of Adjunctive Aripeprazole: Clinical and Experimental Study. ODEM 2019;07:91-113. [DOI: 10.4236/odem.2019.73008] [Reference Citation Analysis]
56 Onwumere J, Shiers D, Gaughran F. Physical Health Problems in Psychosis: Is It Time to Consider the Views of Family Carers? Front Psychiatry 2018;9:668. [PMID: 30574099 DOI: 10.3389/fpsyt.2018.00668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
57 Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci 2018;20:63-73. [PMID: 29946213 [PMID: 29946213 DOI: 10.31887/dcns.2018.20.1/bpenninx] [Cited by in Crossref: 152] [Cited by in F6Publishing: 156] [Article Influence: 30.4] [Reference Citation Analysis]
58 Simoons M, Seldenrijk A, Mulder H, Birkenhäger T, Groothedde-Kuyvenhoven M, Kok R, Kramers C, Verbeeck W, Westra M, van Roon E, Bakker R, Ruhé H. Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. Drug Saf 2018;41:655-64. [PMID: 29484613 DOI: 10.1007/s40264-018-0649-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
59 Johnson CF, Nassr OA, Harpur C, Kenicer D, Thom A, Akram G. Benzodiazepine and z-hypnotic prescribing from acute psychiatric inpatient discharge to long-term care in the community. Pharm Pract (Granada) 2018;16:1256. [PMID: 30416628 DOI: 10.18549/PharmPract.2018.03.1256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
60 Simoons M, Mulder H, Doornbos B, Schoevers RA, van Roon EN, Ruhé HG. Monitoring of somatic parameters at outpatient departments for mood and anxiety disorders. PLoS One 2018;13:e0200520. [PMID: 30130372 DOI: 10.1371/journal.pone.0200520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Coughlin M, Goldie CL, Tranmer J, Khalid-Khan S, Tregunno D. Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics. Can J Psychiatry 2018;63:240-9. [PMID: 29528720 DOI: 10.1177/0706743717751693] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
62 Patterson S, Freshwater K, Goulter N, Ewing J, Leamon B, Choudhary A, Moudgil V, Emmerson B. Psychiatrists' follow-up of identified metabolic risk: a mixed-method analysis of outcomes and influences on practice. BJPsych Bull 2016;40:249-55. [PMID: 27752343 DOI: 10.1192/pb.bp.114.049379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
63 Doherty AM. Psychiatric aspects of diabetes mellitus. BJPsych advances 2015;21:407-16. [DOI: 10.1192/apt.bp.114.013532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 Suetani S, Vancampfort D. Schizophrenia and Exercise. Exercise-Based Interventions for Mental Illness 2018. [DOI: 10.1016/b978-0-12-812605-9.00004-6] [Reference Citation Analysis]
65 Mangurian C, Niu GC, Schillinger D, Newcomer JW, Dilley J, Handley MA. Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness. Implement Sci 2017;12:134. [PMID: 29137666 DOI: 10.1186/s13012-017-0663-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
66 Yarborough BJH, Perrin NA, Stumbo SP, Muench J, Green CA. Preventive Service Use Among People With and Without Serious Mental Illnesses. Am J Prev Med 2018;54:1-9. [PMID: 29056371 DOI: 10.1016/j.amepre.2017.08.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
67 Zolezzi M, Abdulrhim S, Isleem N, Zahrah F, Eltorki Y. Medical comorbidities in patients with serious mental illness: a retrospective study of mental health patients attending an outpatient clinic in Qatar. Neuropsychiatr Dis Treat 2017;13:2411-8. [PMID: 28979128 DOI: 10.2147/NDT.S141448] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
68 Ilyas A, Chesney E, Patel R. Improving life expectancy in people with serious mental illness: should we place more emphasis on primary prevention? Br J Psychiatry 2017;211:194-7. [PMID: 28882826 DOI: 10.1192/bjp.bp.117.203240] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
69 de Silva P. How to improve psychiatric services: a perspective from critical psychiatry. British Journal of Hospital Medicine 2017;78:503-7. [DOI: 10.12968/hmed.2017.78.9.503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Pringsheim T, Kelly M, Urness D, Teehan M, Ismail Z, Gardner D. Physical Health and Drug Safety in Individuals with Schizophrenia. Can J Psychiatry 2017;62:673-83. [PMID: 28718324 DOI: 10.1177/0706743717719898] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
71 Asaad T, Meguid MA, El Missiry M, Ali R, Bassim RE, Taha S. Metabolic dysfunction related to typical and atypical antipsychotics in drug-naive patients with nonaffective psychosis. Middle East Current Psychiatry 2017;24:93-101. [DOI: 10.1097/01.xme.0000516722.23761.98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Westman J, Eriksson SV, Gissler M, Hällgren J, Prieto ML, Bobo WV, Frye MA, Erlinge D, Alfredsson L, Ösby U. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol Psychiatr Sci 2018;27:519-27. [PMID: 28580898 DOI: 10.1017/S2045796017000166] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 11.5] [Reference Citation Analysis]
73 Strassnig M, Kotov R, Cornaccio D, Fochtmann L, Harvey PD, Bromet EJ. Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. Bipolar Disord 2017;19:336-43. [PMID: 28574189 DOI: 10.1111/bdi.12505] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
74 Mugisha J, De Hert M, Stubbs B, Basangwa D, Vancampfort D. Physical health policies and metabolic screening in mental health care systems of sub-Saharan African countries: a systematic review. Int J Ment Health Syst 2017;11:31. [PMID: 28428816 DOI: 10.1186/s13033-017-0141-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
75 Ruiz LM, Damron M, Jones KB, Weedon D, Carbone PS, Bakian AV, Bilder DA. Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home. J Autism Dev Disord 2016;46:1887-94. [PMID: 26818535 DOI: 10.1007/s10803-016-2712-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
76 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. Therapie psychischer Erkrankungen 2017. [DOI: 10.1016/b978-3-437-24909-9.16001-3] [Reference Citation Analysis]
77 Holt RI, Citrome L. Psychiatric Disorders and Diabetes. Textbook of Diabetes 2016. [DOI: 10.1002/9781118924853.ch57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Ronsley R, Nguyen D, Davidson J, Panagiotopoulos C. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Can J Psychiatry 2015;60:441-50. [PMID: 26720191 DOI: 10.1177/070674371506001005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
79 Fischler I, Riahi S, Stuckey MI, Klassen PE. Implementation of a clinical practice guideline for schizophrenia in a specialist mental health center: an observational study. BMC Health Serv Res 2016;16:372. [PMID: 27514778 DOI: 10.1186/s12913-016-1618-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
80 Kreyenbuhl JA, Medoff DR, McEvoy JP, Smith TE, Hackman AL, Nossel IR, Dixon LB, Essock SM, Buchanan RW. The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia. Psychiatr Serv 2016;67:1300-6. [PMID: 27364816 DOI: 10.1176/appi.ps.201500438] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
81 Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166-74. [PMID: 27265707 DOI: 10.1002/wps.20309] [Cited by in Crossref: 372] [Cited by in F6Publishing: 392] [Article Influence: 53.1] [Reference Citation Analysis]
82 Foley DL, Mackinnon A, Morgan VA, Watts GF, Castle DJ, Waterreus A, Galletly CA. Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis. Schizophr Bull 2016;42:1280-9. [PMID: 27150636 DOI: 10.1093/schbul/sbw027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
83 Happell B, Platania-Phung C, Gaskin CJ, Stanton R. Use of an electronic metabolic monitoring form in a mental health service - a retrospective file audit. BMC Psychiatry 2016;16:109. [PMID: 27095252 DOI: 10.1186/s12888-016-0814-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
84 Kreyenbuhl J, Dixon LB, Brown CH, Medoff DR, Klingaman EA, Fang LJ, Tapscott S, Walsh MB. A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications. Community Ment Health J 2017;53:163-75. [PMID: 27061185 DOI: 10.1007/s10597-016-0007-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
85 Hansen MV, Hjorth P, Kristiansen CB, Vandborg K, Gustafsson LN, Munk-jørgensen P. Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia. Int J Soc Psychiatry 2016;62:369-76. [DOI: 10.1177/0020764016636277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
86 Ewart SB, Bocking J, Happell B, Platania-Phung C, Stanton R. Mental Health Consumer Experiences and Strategies When Seeking Physical Health Care: A Focus Group Study. Glob Qual Nurs Res 2016;3:2333393616631679. [PMID: 28462330 DOI: 10.1177/2333393616631679] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
87 Stomski NJ, Morrison P, Meehan T. Assessing clinicians' perspectives about the identification and management of antipsychotic medication side-effects: Psychometric evaluation of a survey questionnaire. Int J Ment Health Nurs 2016;25:171-9. [PMID: 26834074 DOI: 10.1111/inm.12216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
88 Samaras K. Cardiometabolic Risk and Monitoring in Psychiatric Disorders. Cardiovascular Diseases and Depression 2016. [DOI: 10.1007/978-3-319-32480-7_18] [Reference Citation Analysis]
89 Quintana DS, Westlye LT, Kaufmann T, Rustan ØG, Brandt CL, Haatveit B, Steen NE, Andreassen OA. Reduced heart rate variability in schizophrenia and bipolar disorder compared to healthy controls. Acta Psychiatr Scand 2016;133:44-52. [PMID: 26371411 DOI: 10.1111/acps.12498] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
90 Plever S, McCarthy I, Anzolin M, Emmerson B, Khatun M. A collaborative approach to improve the assessment of physical health in adult consumers with schizophrenia in Queensland mental health services. Australas Psychiatry 2016;24:55-61. [PMID: 26432652 DOI: 10.1177/1039856215608285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Barnes TR, Bhatti SF, Adroer R, Paton C. Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK. BMJ Open 2015;5:e007633. [PMID: 26428329 DOI: 10.1136/bmjopen-2015-007633] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
92 Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339-347. [PMID: 26407790 DOI: 10.1002/wps.20252] [Cited by in Crossref: 661] [Cited by in F6Publishing: 696] [Article Influence: 82.6] [Reference Citation Analysis]
93 Hor ES, Subramaniam S, Koay JM, Bharathy A, Vasudevan U, Panickulam JJ, Ng I, Arif NH, Russell V. Improving metabolic monitoring in patients maintained on antipsychotics in Penang, Malaysia. Australas Psychiatry 2016;24:67-71. [PMID: 26400455 DOI: 10.1177/1039856215604484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
94 Burghardt KJ, Goodrich JM, Dolinoy DC, Ellingrod VL. DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. Epigenomics 2015;7:343-52. [PMID: 26077424 DOI: 10.2217/epi.15.5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
95 Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015;132:144-57. [PMID: 25943829 DOI: 10.1111/acps.12439] [Cited by in Crossref: 150] [Cited by in F6Publishing: 155] [Article Influence: 18.8] [Reference Citation Analysis]
96 Holt RI. The prevention of diabetes and cardiovascular disease in people with schizophrenia. Acta Psychiatr Scand 2015;132:86-96. [PMID: 25976975 DOI: 10.1111/acps.12443] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
97 Mitchell AJ, De Hert M. Promotion of physical health in persons with schizophrenia: can we prevent cardiometabolic problems before they begin? Acta Psychiatr Scand 2015;132:83-5. [PMID: 26177260 DOI: 10.1111/acps.12466] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
98 Baller JB, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL. Screening for cardiovascular risk factors in adults with serious mental illness: a review of the evidence. BMC Psychiatry 2015;15:55. [PMID: 25885367 DOI: 10.1186/s12888-015-0416-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
99 Brown JD, Barrett A, Hourihan K, Caffery E, Ireys HT. State Variation in the Delivery of Comprehensive Services for Medicaid Beneficiaries with Schizophrenia and Bipolar Disorder. Community Ment Health J 2015;51:523-34. [PMID: 25786723 DOI: 10.1007/s10597-015-9857-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
100 Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig 2015;12:242-8. [PMID: 25866526 DOI: 10.4306/pi.2015.12.2.242] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
101 Wong-anuchit C. Clinical Management of Antipsychotic-Induced Hyperprolactinemia: Clinical Management of Antipsychotic-Induced Hyperprolactinemia. Perspect Psychiatr Care 2016;52:145-52. [DOI: 10.1111/ppc.12111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
102 Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry 2015;14:56-63. [PMID: 25655159 DOI: 10.1002/wps.20187] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 8.5] [Reference Citation Analysis]
103 Cotes RO, de Nesnera A, Kelly M, Orsini K, Xie H, McHugo G, Bartels S, Brunette MF. Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System. Community Ment Health J 2015;51:685-94. [PMID: 25645893 DOI: 10.1007/s10597-015-9833-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
104 Stubbs B, Eggermont L, Mitchell AJ, De Hert M, Correll CU, Soundy A, Rosenbaum S, Vancampfort D. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatr Scand 2015;131:75-88. [PMID: 25098864 DOI: 10.1111/acps.12325] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 7.0] [Reference Citation Analysis]
105 Tzeng NS, Hsu YH, Ho SY, Kuo YC, Lee HC, Yin YJ, Chen HA, Chen WL, Chu WC, Huang HL. Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study. BMJ Open 2015;5:e006777. [PMID: 25628048 DOI: 10.1136/bmjopen-2014-006777] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
106 Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 10. Auflage. Therapie Psychischer Erkrankungen 2015. [DOI: 10.1016/b978-3-437-24906-8.16001-6] [Reference Citation Analysis]
107 Ronsley R, Chow L, Kuss K, Davidson J, Panagiotopoulos C. Ensuring the Safety of Children Treated with Second-Generation Antipsychotics. The Science and Ethics of Antipsychotic Use in Children 2015. [DOI: 10.1016/b978-0-12-800016-8.00004-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Fleischhacker WW, Arango C, Arteel P, Barnes TR, Carpenter W, Duckworth K, Galderisi S, Halpern L, Knapp M, Marder SR, Moller M, Sartorius N, Woodruff P. Schizophrenia--time to commit to policy change. Schizophr Bull 2014;40 Suppl 3:S165-94. [PMID: 24778411 DOI: 10.1093/schbul/sbu006] [Cited by in Crossref: 104] [Cited by in F6Publishing: 114] [Article Influence: 11.6] [Reference Citation Analysis]
109 Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat 2015;11:51-7. [PMID: 25565850 DOI: 10.2147/NDT.S75449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
110 Miller BJ, Kandhal P, Rapaport MH, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. Brain Behav Immun 2015;45:28-35. [PMID: 25542737 DOI: 10.1016/j.bbi.2014.12.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
111 Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-induced metabolic disturbances in the elderly. Drugs Aging 2014;31:159-84. [PMID: 24477569 DOI: 10.1007/s40266-014-0152-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
112 Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11:79-89. [PMID: 25445848 DOI: 10.1038/nrendo.2014.203] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 9.8] [Reference Citation Analysis]
113 Shulman M, Miller A, Misher J, Tentler A. Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach. J Multidiscip Healthc. 2014;7:489-501. [PMID: 25382979 DOI: 10.2147/jmdh.s49817] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
114 Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry 2014;5:137. [PMID: 25309466 DOI: 10.3389/fpsyt.2014.00137] [Cited by in Crossref: 183] [Cited by in F6Publishing: 199] [Article Influence: 20.3] [Reference Citation Analysis]
115 Richly P, López P, Gleichgerrcht E, Flichtentrei D, Prats M, Mastandueno R, Bustin J, Cetkovich-Bakmas M. Psychiatrists’ approach to vascular risk assessment in Latin America. World J Psychiatr 2014; 4(3): 56-61 [PMID: 25250222 DOI: 10.5498/wjp.v4.i3.56] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
116 Saloojee S, Burns JK, Motala AA. Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa. BMC Psychiatry 2014;14:228. [PMID: 25113131 DOI: 10.1186/s12888-014-0228-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
117 Gerhard T, Akincigil A, Correll CU, Foglio NJ, Crystal S, Olfson M. National trends in second-generation antipsychotic augmentation for nonpsychotic depression. J Clin Psychiatry 2014;75:490-7. [PMID: 24500284 DOI: 10.4088/JCP.13m08675] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
118 Bailey DS, Smith G. Why 'parity of esteem' for mental health is every hospital doctor's concern. Br J Hosp Med (Lond) 2014;75:277-80. [PMID: 25040273 DOI: 10.12968/hmed.2014.75.5.277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
119 Vassas TJ, Burghardt KJ, Ellingrod VL. Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics 2014;15:61-7. [PMID: 24329191 DOI: 10.2217/pgs.13.157] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
120 Gerolamo AM, Kim JY, Brown JD, Schuster J, Kogan J. Implementation of a Reverse Colocation Model: Lessons from Two Community Behavioral Health Agencies in Rural Pennsylvania. J Behav Health Serv Res 2016;43:443-58. [PMID: 24981219 DOI: 10.1007/s11414-014-9423-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
121 van Hasselt FM, Thier CS, van Rijswijk E, Loonen AJ. Is Somatic Health Screening in Patients With Severe Mental Illness of Added Value? Perspect Psychiatr Care 2014;50:186-192. [DOI: 10.1111/ppc.12042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Kim EY, Kim SH, Lee NY, Yoon JS, Kim CE, Kim YS, Ahn YM. Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia. Psychopharmacology (Berl) 2014;231:4479-87. [PMID: 24819732 DOI: 10.1007/s00213-014-3601-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Ferrara M, Umlauf A, Sanders C, Meyer JM, Allen McCutchan J, Duarte N, Hampton Atkinson J, Grant I, Ellis RJ; CHARTER Group. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res 2014;218:201-8. [PMID: 24794030 DOI: 10.1016/j.psychres.2014.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
124 Bannister E, Nakonezny P, Byerly M. Curricula for teaching clinical practice guidelines in US psychiatry residency and child and adolescent fellowship programs: a survey study. Acad Psychiatry 2014;38:198-204. [PMID: 24619912 DOI: 10.1007/s40596-014-0057-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
125 Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkankungen, 9. Auflage. Therapie Psychischer Erkrankungen 2014. [DOI: 10.1016/b978-3-437-24905-1.16001-0] [Reference Citation Analysis]
126 Foley DL, Mackinnon A, Watts GF, Shaw JE, Magliano DJ, Castle DJ, McGrath JJ, Waterreus A, Morgan VA, Galletly CA. Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender. PLoS One 2013;8:e82606. [PMID: 24367528 DOI: 10.1371/journal.pone.0082606] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
127 Vanderlip ER, Williams NA, Fiedorowicz JG, Katon W. Exploring primary care activities in ACT teams. Community Ment Health J 2014;50:466-73. [PMID: 24337472 DOI: 10.1007/s10597-013-9673-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
128 Murphy AL, Gardner DM, Kisely S, Cooke C, Kutcher SP, Hughes J. Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain. ISRN Obes 2013;2013:390130. [PMID: 24533223 DOI: 10.1155/2013/390130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
129 Birnbaum ML, Saito E, Gerhard T, Winterstein A, Olfson M, Kane JM, Correll CU. Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. Curr Psychiatry Rep 2013;15:382. [PMID: 23881713 DOI: 10.1007/s11920-013-0382-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
130 Owen RR, Drummond KL, Viverito KM, Marchant K, Pope SK, Smith JL, Landes RD. Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation. Implement Sci 2013;8:120. [PMID: 24103648 DOI: 10.1186/1748-5908-8-120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
131 Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, Probst M, De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12:240-50. [PMID: 24096790 DOI: 10.1002/wps.20069] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 17.7] [Reference Citation Analysis]
132 Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 2013;3:33-51. [PMID: 23983991 DOI: 10.1177/2045125312464385] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 6.8] [Reference Citation Analysis]
133 Burghardt KJ, Ellingrod VL. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate? Mol Diagn Ther 2013;17:21-30. [PMID: 23341251 DOI: 10.1007/s40291-013-0017-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
134 Lang DJ, Barr AM, Procyshyn RM. Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. Curr Cardiovasc Risk Rep 2013;7:283-7. [PMID: 23864926 DOI: 10.1007/s12170-013-0321-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
135 Skelton M, Thacker S, Forbes-haley A, Kumar M, Holliday E. Psychiatrists' access to electronic laboratory results. Psychiatrist 2013;37:160-163. [DOI: 10.1192/pb.bp.112.040543] [Reference Citation Analysis]
136 Duval F. Affections métaboliques et psychiatrie. EMC - Psychiatrie 2013;10:1-17. [DOI: 10.1016/s0246-1072(13)60022-x] [Reference Citation Analysis]
137 Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 2013;3:e002808. [PMID: 23599376 DOI: 10.1136/bmjopen-2013-002808] [Cited by in Crossref: 135] [Cited by in F6Publishing: 150] [Article Influence: 13.5] [Reference Citation Analysis]
138 Deuschle M, Paul F, Brosz M, Bergemann N, Franz M, Kammerer-Ciernioch J, Lautenschlager M, Lederbogen F, Roesch-Ely D, Weisbrod M, Kahl KG, Reichmann J, Gross J, Umbreit J. Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study. Soc Psychiatry Psychiatr Epidemiol 2013;48:1283-8. [PMID: 23515714 DOI: 10.1007/s00127-013-0676-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
139 Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl) 2013;226:1-12. [PMID: 23344556 DOI: 10.1007/s00213-013-2982-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
140 Gordon PC, Xavier JC, Louzã MR. Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia. Neuropsychiatr Dis Treat 2013;9:133-8. [PMID: 23355783 DOI: 10.2147/NDT.S37019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
141 Chwastiak L, Cruza-Guet MC, Carroll-Scott A, Sernyak M, Ickovics J. Preventive counseling for chronic disease: missed opportunities in a community mental health center. Psychosomatics 2013;54:328-35. [PMID: 23274008 DOI: 10.1016/j.psym.2012.10.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
142 Papanastasiou E. Interventions for the metabolic syndrome in schizophrenia: a review. Ther Adv Endocrinol Metab 2012;3:141-62. [PMID: 23185687 DOI: 10.1177/2042018812458697] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
143 Morrato EH. An update on lipid profile screening in second-generation antipsychotic users in the USA. Clinical Lipidology 2012;7:509-523. [DOI: 10.2217/clp.12.51] [Reference Citation Analysis]
144 Miller BJ, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun 2013;31:82-9. [PMID: 22982547 DOI: 10.1016/j.bbi.2012.08.016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
145 Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39:295-305. [PMID: 22927670 DOI: 10.1093/schbul/sbs082] [Cited by in Crossref: 202] [Cited by in F6Publishing: 213] [Article Influence: 18.4] [Reference Citation Analysis]
146 Binford SH, Johnson MD, Kennedy RS, Leffler JB. Clinician Education Improves Lipid Monitoring in Patients Taking Second-Generation Antipsychotic Agents, Nationally and Locally. Health Outcomes Research in Medicine 2012;3:e121-e137. [DOI: 10.1016/j.ehrm.2012.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
147 De Hert M, Vancampfort D, Correll CU, Peuskens J, van Winkel R, Mitchell AJ. Authors' reply. Br J Psychiatry 2012;201:76-77. [DOI: 10.1192/bjp.201.1.76] [Reference Citation Analysis]
148 Vancampfort D, Probst M, Scheewe T, Knapen J, De Herdt A, De Hert M. The functional exercise capacity is correlated with global functioning in patients with schizophrenia. Acta Psychiatr Scand 2012;125:382-7. [PMID: 22235778 DOI: 10.1111/j.1600-0447.2011.01825.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
149 Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther 2011;33:B16-39. [PMID: 22177377 DOI: 10.1016/j.clinthera.2011.11.016] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
150 van Gool R, van Meijel B. Mind the body! NED TIJDS EVID PRACT 2012;10:4-8. [DOI: 10.1007/s12468-012-0011-x] [Reference Citation Analysis]
151 De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114-126. [PMID: 22009159 DOI: 10.1038/nrendo.2011.156] [Cited by in Crossref: 637] [Cited by in F6Publishing: 684] [Article Influence: 53.1] [Reference Citation Analysis]